» Articles » PMID: 30651225

Phage Therapy in the Postantibiotic Era

Overview
Specialty Microbiology
Date 2019 Jan 18
PMID 30651225
Citations 367
Authors
Affiliations
Soon will be listed here.
Abstract

Antibiotic resistance is arguably the biggest current threat to global health. An increasing number of infections are becoming harder or almost impossible to treat, carrying high morbidity, mortality, and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the multidimensional strategies to combat antibiotic resistance. Although phage therapy was first implemented almost a century ago, it was brought to a standstill after the successful introduction of antibiotics. Now, with the rise of antibiotic resistance, phage therapy is experiencing a well-deserved rebirth. Among the admittedly vast literature recently published on this topic, this review aims to provide a forward-looking perspective on phage therapy and its role in modern society. We cover the key points of the antibiotic resistance crisis and then explain the biological and evolutionary principles that support the use of phages, their interaction with the immune system, and a comparison with antibiotic therapy. By going through up-to-date reports and, whenever possible, human clinical trials, we examine the versatility of phage therapy. We discuss conventional approaches as well as novel strategies, including the use of phage-antibiotic combinations, phage-derived enzymes, exploitation of phage resistance mechanisms, and phage bioengineering. Finally, we discuss the benefits of phage therapy beyond the clinical perspective, including opportunities for scientific outreach and effective education, interdisciplinary collaboration, cultural and economic growth, and even innovative use of social media, making the case that phage therapy is more than just an alternative to antibiotics.

Citing Articles

Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.

Kim M, Suh G, Cullen G, Perez Rodriguez S, Dharmaraj T, Chang T J Clin Invest. 2025; 135(5).

PMID: 40026251 PMC: 11870740. DOI: 10.1172/JCI187996.


Oral bacteriophages and their potential as adjunctive treatments for periodontitis: a narrative review.

Kabwe M, Tucci J, Darby I, Dashper S J Oral Microbiol. 2025; 17(1):2469890.

PMID: 40013014 PMC: 11864011. DOI: 10.1080/20002297.2025.2469890.


Characterization and genome analysis of novel Klebsiella pneumoniae phage vbKpUKJ_2 isolated from hospital sewage water.

Mirza K, Tchatchiashvili T, Marquet M, Nietzsche S, Pletz M, Makarewicz O BMC Microbiol. 2025; 25(1):96.

PMID: 40011819 PMC: 11863478. DOI: 10.1186/s12866-025-03813-y.


Isolation and characterization of a novel lytic phage K14-2 infecting diverse species of the genus and .

Kang S, Han J, Choi Y, Jeong I, Bae J Front Microbiol. 2025; 15:1491516.

PMID: 39895935 PMC: 11782208. DOI: 10.3389/fmicb.2024.1491516.


An insight into the applications of bacteriophages against food-borne pathogens.

Deepa G, Daniel I, Sugumar S J Food Sci Technol. 2025; 62(1):1-10.

PMID: 39867606 PMC: 11754761. DOI: 10.1007/s13197-024-06070-5.


References
1.
Ganz T, Lehrer R . Antibiotic peptides from higher eukaryotes: biology and applications. Mol Med Today. 1999; 5(7):292-7. DOI: 10.1016/s1357-4310(99)01490-2. View

2.
Grundling A, Blasi U, Young R . Genetic and biochemical analysis of dimer and oligomer interactions of the lambda S holin. J Bacteriol. 2000; 182(21):6082-90. PMC: 94742. DOI: 10.1128/JB.182.21.6082-6090.2000. View

3.
Sulakvelidze A, Alavidze Z, Morris Jr J . Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45(3):649-59. PMC: 90351. DOI: 10.1128/AAC.45.3.649-659.2001. View

4.
Loeffler J, Nelson D, Fischetti V . Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science. 2001; 294(5549):2170-2. DOI: 10.1126/science.1066869. View

5.
Biswas B, Adhya S, Washart P, Paul B, Trostel A, Powell B . Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2001; 70(1):204-10. PMC: 127648. DOI: 10.1128/IAI.70.1.204-210.2002. View